Bioxodes is a clinical-stage biotech company focused on developing innovative therapeutics derived from natural molecules to prevent thrombosis and inflammatory processes. The company operates in the biotechnology sector, targeting healthcare providers and pharmaceutical companies as its primary clients. Bioxodes' business model revolves around research and development, with a strong emphasis on intellectual property. The company generates revenue through the development and commercialization of its high-value products, particularly its lead program based on the Ir CPI molecule, which aims to prevent thrombosis. Founded by experienced healthcare and biotech executives, Bioxodes leverages extensive research and drug development expertise to create novel therapeutic solutions. The company holds issued and pending patents related to Ir CPI in the EU and US, and is committed to expanding its intellectual property portfolio. Bioxodes also has preclinical drug discovery programs in the areas of inflammatory diseases and cardiovascular medicine.

Keywords: thrombosis, inflammation, biotech, natural molecules, therapeutics, Ir CPI, intellectual property, drug development, cardiovascular, healthcare.